US · XTLB
XTL Biopharmaceuticals Ltd.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Ramat Gan 5218102
- Website
- xtlbio.com
Price · as of 2024-12-31
$3.65
Market cap 1.04M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | $1.34 | -63.29% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $15.00 | ||||
| 2011 | $23.50 | ||||
| 2012 | $32.85 | $11.17 | $0.74 | ||
| 2013 | $19.05 | $227.77 | $77,245.70 | $0.00 | $0.00 |
| 2014 | $12.30 | $46.28 | |||
| 2015 | $6.80 | ||||
| 2016 | $2.60 | ||||
| 2017 | $1.70 | ||||
| 2018 | $2.25 | ||||
| 2019 | $1.19 | ||||
| 2020 | $3.39 | ||||
| 2021 | $2.25 | ||||
| 2022 | $1.28 | ||||
| 2023 | $0.92 | ||||
| 2024 | $1.25 | $1.34 | $0.00 |
AI valuation
Our deep-learning model estimates XTL Biopharmaceuticals Ltd.'s (XTLB) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $3.65
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$1.34
-63.29% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| XTLB | XTL Biopharmaceuticals Lt… | $3.65 | 1.04M | — | -63% | — | — | -2.05 | 0.39 | 4.66 | -1.18 | — | -1.34 | 0.67% | -481.60% | -227.72% | -26.83% | -83.03% | -18.71% | 0.03 | -25.26 | 0.61 | 0.56 | 0.25 | — | — | 13649.00% | -79.50% | -0.73 | -72.01% | 0.00% | 0.00% | 0.00% | -0.51 | -0.66 | 2.44 | -26.54 |
| CYCN | Cyclerion Therapeutics, I… | $1.35 | 5.14M | — | +2,196,706% | — | — | -2.31 | 0.80 | 3.53 | -1.05 | — | 0.80 | 100.00% | -181.40% | -152.85% | -30.36% | -77.73% | -26.64% | 0.00 | — | 5.83 | 5.22 | 0.89 | -8654.00% | — | -7960.00% | -61.46% | -5.98 | -92.83% | 0.00% | 0.00% | 0.00% | -1.05 | -0.88 | 1.91 | -33.88 |
| ENSC | Ensysce Biosciences, Inc. | $0.62 | 1.48M | +2,572,138,798% | +223% | — | — | -1.10 | 2.36 | 1.68 | -0.83 | — | 2.36 | -38.57% | -129.17% | -153.30% | -471.83% | 16069.72% | -192.33% | 0.08 | -5.22 | 2.42 | 1.64 | 0.48 | -256.00% | 13353.00% | 6959834645.00% | -85550186.53% | -3399198.17 | 17914756446.99% | 3306.75% | -3630.90% | 3340.18% | -0.83 | 0.00 | 1.07 | -32.39 |
| KALA | KALA BIO, Inc. | $0.38 | 8.33M | — | — | — | — | -1.01 | 3.16 | — | -0.49 | — | 3.16 | 0.00% | — | — | -388.29% | 599.82% | -69.12% | 2.62 | -7.09 | 3.11 | 3.02 | 0.46 | -5977.00% | — | 369.00% | -76.03% | -1.73 | 433.08% | 0.00% | 0.00% | 11.20% | -0.49 | -0.68 | — | -17.97 |
| KTTA | Pasithea Therapeutics Cor… | $0.88 | 6.56M | — | — | — | — | -0.09 | 0.09 | — | 0.41 | — | 0.21 | 0.00% | — | — | -72.83% | -189.89% | -65.93% | 0.00 | — | 6.58 | 6.18 | 0.51 | -246.00% | — | 345.00% | -1067.47% | -12.43 | -185.53% | 0.00% | 0.00% | 0.00% | 0.39 | 0.40 | — | -6.17 |
| PLRZ | Polyrizon Ltd. | $12.49 | 13.01M | — | — | — | — | -8.81 | 2.58 | — | -7.77 | — | 5.67 | 0.00% | — | — | -57.83% | -88.33% | -50.61% | 0.00 | -434.00 | 10.16 | 9.79 | 1.79 | — | — | 11359.00% | -8.43% | -4.39 | -77.82% | 0.00% | 0.00% | 20.20% | -8.49 | -9.64 | — | 29.76 |
| QNRX | Quoin Pharmaceuticals, Lt… | $8.37 | 4.92M | — | — | — | — | -0.16 | 0.16 | — | 1.34 | — | 0.17 | 0.00% | — | — | -121.13% | 192.82% | -64.60% | 0.00 | — | 3.57 | 3.36 | 0.38 | -8019.00% | — | -9.00% | -540.58% | -1.88 | 159.01% | 0.00% | 0.00% | 84.08% | 1.32 | 1.60 | — | -5.96 |
| RADX | Radiopharm Theranostics L… | $4.99 | 6.43M | +1,761% | — | — | — | — | 1.36 | 16.76 | -0.83 | — | -34.17 | 1.08% | -1050.63% | -1055.27% | 0.00% | -302.69% | 0.00% | 0.00 | -584.59 | 2.67 | 2.65 | 0.76 | -8533.00% | 111427.00% | 5950.00% | -60.17% | -2.45 | -290.58% | 0.00% | — | 17.31% | -0.83 | -0.87 | 8.75 | -2.59 |
| TCRT | Alaunos Therapeutics, Inc… | $3.19 | 7.12M | +18,244% | -80% | — | — | -0.55 | 1.26 | 259.40 | -0.32 | — | 1.26 | 100.00% | -48120.00% | -46790.00% | -111.80% | -790.80% | -84.93% | 0.00 | — | 3.98 | 1.58 | 0.23 | -8671.00% | 10000.00% | -8362.00% | -191.63% | -7.18 | -816.93% | 0.00% | 0.00% | 0.00% | -0.31 | -0.30 | 150.30 | -470.35 |
| VYNE | VYNE Therapeutics Inc. | $0.60 | 10.01M | +3,912% | -43% | — | — | -0.98 | 0.93 | 45.39 | 0.12 | — | 0.93 | 0.00% | -4690.53% | -4646.14% | -66.33% | 505.69% | -54.57% | 0.00 | — | 12.53 | 12.11 | 0.90 | -3404.00% | 1377.00% | -283.00% | -128.02% | -13.83 | 626.52% | 0.00% | 0.00% | 16.23% | 0.12 | 0.09 | -5.50 | -30.50 |
About XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
- CEO
- Noam Band
- Employees
- 10
- Beta
- 0.81
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($1.34 ÷ $3.65) − 1 = -63.29% (DCF, example).